Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Scheduling (national classification system) (56)
- Committees and advisory bodies (45)
- Safety monitoring and information (12)
- Advertising (9)
- Manufacturing (9)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Clinical trials (3)
- Legislation (3)
- Medicinal cannabis hub (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
247 result(s) found, displaying 201 to 225
-
Scheduling submissionsPublic submissions on matters referred to the July 2017 scheduling meetings, and received during the pre-meeting and interim decision consultation periods, are now available
-
Scheduling submissionsPublic submissions on interim scheduling decisions for substances referred to the November 2017 ACMS/ACCS meetings are now available
-
Corporate reportsReport detailing prescription medicines registrations for 2017
-
Corporate reportsNew generic medicines and biosimilar medicines registered in 2017
-
Corporate reportsA step-by-step guide for prescription medicines
-
Scheduling submissionsPublic submissions on matters referred to the March 2017 scheduling meetings, and received during the pre-meeting and interim decision consultation periods, are now available
-
Corporate reportsThis document reflects the evidence supporting the use of medicinal cannabis in treating chronic pain and the recommendations of the Chronic Pain Working Group
-
Corporate reportsTGA Stakeholder Survey 2016-17 - questions and answers
-
Corporate reportsSummary of generic and biosimilar prescription medicines registered in Australia in 2016
-
Corporate reportsThe TGA's scientific review on the safety of nanoparticles in sunscreens.
-
Corporate reportsRegulation impact statement: Codeine re-scheduling
-
Corporate reportsEconomic modelling and financial quantification of the regulatory impact of proposed changes to codeine scheduling
-
Corporate reportsRegulation impact statement: General requirements for labels for medicines
-
Corporate reportsThese annual summaries provide details of new prescription medicines registrations and information on new or extended uses for existing medicines.
-
Corporate reportsInfographic - Half Yearly Performance Snapshot - 1 July to 31 December 2015
-
Corporate reportsOTC application placement question and answer tool
-
Corporate reportsReporting medical device adverse incidents
-
Corporate reportsEach year, approximately 40 new prescription medicines containing new active substances are registered.
-
Corporate reportsThe Scheduling Policy Framework (SPF) is a key feature of the revised arrangements for scheduling of medicines and chemicals
-
Scheduling submissionsPublic submissions on scheduling matters referred to the ACMS
-
Corporate reportsThis statement guides decision making to help address concerns with joint replacement prostheses.
-
Scheduling submissionsPublic submissions on scheduling matters referred to the ACCS#10 and the joint ACCS-ACMS#8
-
Scheduling submissionsPublic submissions on scheduling matters referred to ACMS
-
Corporate reportsTGA approach to disclosure of commercially confidential information (CCI)
-
Scheduling submissionsPublic submissions on scheduling matters referred to ACCS, ACMS and the joint ACCS-ACMS